[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623996":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":45,"responsibleParty":68,"collaborators":70,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":26,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":26,"overallStatus":93,"whyStopped":26,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"NHS Greater Glasgow and Clyde","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"rTMS (Left Inferior Parietal Lobule)","EXPERIMENTAL","Participants receive active repetitive transcranial magnetic stimulation (rTMS) targeted to the left inferior parietal lobule (L-IPL). Stimulation is delivered at 10 Hz, 90% resting motor threshold, 1200 pulses per session, across 12 sessions over 4 weeks. This arm is designed to evaluate whether neuromodulation of the L-IPL alters immune signalling and reduces persistent pain in psoriatic arthritis.",[13],"Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS)",{"label":15,"type":16,"description":17,"interventionNames":18},"rTMS (Vertex Stimulation)","SHAM_COMPARATOR","Participants receive control rTMS delivered to the cranial vertex, a site not expected to modulate neuroimmune pathways relevant to pain. Stimulation parameters match the active arm (10 Hz, 90% resting motor threshold, 1200 pulses per session, 12 sessions over 4 weeks). This arm controls for nonspecific effects of rTMS, including sensory experience and participant expectations.",[19],"Device: Control Repetitive Transcranial Magnetic Stimulation (rTMS)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Active Repetitive Transcranial Magnetic Stimulation (rTMS)","rTMS delivered to the left inferior parietal lobule at 10 Hz, 90% resting motor threshold, 1200 pulses per session, for 12 sessions over 4 weeks.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Control Repetitive Transcranial Magnetic Stimulation (rTMS)","rTMS delivered to the cranial vertex using identical stimulation parameters to the active arm, serving as a control condition.",[15],[32],{"name":33,"affiliation":34,"role":35},"Flavia Sunzini, MD","University of Glasgow","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Maxine Arnott, BSc","CONTACT","07890 059695","Maxine.Arnott@glasgow.ac.uk",{"name":43,"role":39,"phone":26,"phoneExt":26,"email":44},"Neil Basu, MD","Neil.Basu@glasgow.ac.uk",[46],{"facility":47,"status":26,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Queen Elizabeth University Hospital","Glasgow","Scotland","G51 4TF","United Kingdom","UK",{"type":54,"coordinates":55},"Point",[56,57],-4.25763,55.86515,{"lat":57,"lon":56},[60,63,64,66],{"name":61,"role":39,"phone":26,"phoneExt":26,"email":62},"Maxine Arnott","maxine.arnott@glasgow.ac.uk",{"name":33,"role":35,"phone":26,"phoneExt":26,"email":26},{"name":43,"role":65,"phone":26,"phoneExt":26,"email":26},"SUB_INVESTIGATOR",{"name":67,"role":65,"phone":26,"phoneExt":26,"email":26},"Edwin Robertson, MD",{"type":69,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[71],{"name":72,"class":73},"Chief Scientist Office of the Scottish Government","OTHER_GOV","100623996","rewiring-the-brain-immune-axis-for-chronic-pain-using-transcranial-magnetic-stimulation-in-psoriatic-arthritis-100623996",false,"NCT07403890","Rewiring the Brain-Immune Axis for Chronic Pain Using Transcranial Magnetic Stimulation in Psoriatic Arthritis","REACT","Inclusion Criteria:\n\n* Adults ≥ 18 years ≤ 75 years\n* Diagnosis of PsA according to CASPAR (Classification Criteria for Psoriatic Arthritis).\n* Low disease activity (no more than one joint with clinically active swelling) or remission\n* Chronic pain for at least 3 months and VAS (Visual Analogue Scale) pain ≥30 mm\n* Stable treatment ≥3 months prior to entering the study\n* Able and willing to maintain medication for the duration study\n* Able to undergo MRI and TMS procedures\n\nExclusion Criteria:\n\n* Inability to provide written informed consent.\n* Severe physical impairment (e.g. blindness, deafness, paraplegia) Pregnant, planning pregnancy or breast feeding.\n* Severe claustrophobia precluding MRI.\n* Contraindications to MRI (e.g. metal implants\u002F pacemaker).\n* Contraindications to TMS (e.g. history of seizures).\n* Serious infection including sepsis, tuberculosis and opportunistic infections such as invasive fungal infections.\n* Major confounding neurological disease including Multiple\n* Sclerosis, Stroke, Traumatic Brain Injury, Parkinson's Disease, Alzheimer's Disease","ALL","18 Years","75 Years",{"count":85,"type":86},40,"ESTIMATED","INTERVENTIONAL",[89],"NA","Despite advances in immunomodulatory therapies, many Psoriatic arthritis (PsA) patients experience persistent pain unrelated to clinical active joint inflammation. Recent evidence suggests the Inferior Parietal Lobule (IPL) serves as a neuroimmune hub linking central neural activity with peripheral immune dysregulation. In a prior feasibility study, a single L-IPL-targeted TMS session reduced pain and altered immune signalling in inflammatory arthritis by reducing STAT3 phosphorylation in circulating monocytes. This study builds on those findings by evaluating whether rTMS over 4 weeks can induce sustained immune reprogramming while providing meaningful pain relief.",[92],"Psoriatic Arthritis","NOT_YET_RECRUITING","2026-02-04",{"date":96,"type":97},"2026-02-11","ACTUAL",{"date":99,"type":86},"2026-03-01",{"date":101,"type":86},"2028-03-28",{"name":5,"class":6},1]